Supply Chain

Intravenous nitroglycerin, a drug often found in emergency rooms as a go-to treatment for heart complications, is running short on supply, according to a Medscape report.

The global ophthalmology device market is expected to reach $9.47 billion by 2018, growing at a compound annual growth rate of 6.8 percent, according to a Markets and Markets news release.

 So far, the year 2014 has witnessed 14 medical device recalls.

The following are the latest drugs to be approved by the U.S. Food and Drug Administration over the past two months and compiled on Becker's Hospital Review, beginning with the most recent.

The U.S. Food and Drug Administration has a proposed a rule that would allow reclassification of devices via an administrative order published in the Federal Register.

The US Drug Watchdog, a consumer advocacy group, is urging patients who received a metal-on-metal hip implant to receive an MRI to ensure the implant has not started to fail, according to a Reuters report.

The U.S. Food and Drug Administration's Center for Devices and Radiological Health released its Medical Device Recall Report for FY 2003 to FY 2012, showing device recalls have nearly doubled in the past 10 years.

Todd Ebert, president and CEO of Amerinet, offers four strategies to ensure an efficient supply chain, as reported on Healthcare Finance News.

Pensacola, Fla.-based Baptist Health Care has signed an agreement with Alpharetta, Ga.-based MedAssets to utilize MedAssets' tools to enhance operational efficiency.

The U.S. Food and Drug Administration has approved Otezla (apremilast) for the treatment of psoriatic arthritis in adults.